| Demographic and clinical characteristics of study participants |
| Gender |
Male |
19 (23%) |
|
| |
Female |
63 (77%) |
|
| |
|
|
|
| Age (years) |
Mean (Std Dev) |
36.6 (+/-7.4) |
|
| |
Median (Range) |
36 (23 - 53) |
|
| Clinical presentation |
|
|
| |
Symptomatic |
15 (18%) |
|
| |
Asymptomatic |
67 (82%) |
|
| cART Regimen |
|
|
| |
CBV/NVP |
22 (27%) |
|
| |
CBV/EFV |
21 (26%) |
|
| |
d4T/3TC/NVP |
10 (12%) |
|
| |
d4T/3TC/EFV |
7 (9%) |
|
| |
Other |
22 (27%) |
|
Abbreviations: CBV: Combivir™ (co-formulated zidovudine (ZDV) plus
lamuvidine (3TC)); NVP: nevirapine; EFV: efavirenz; d4T: stavudine; 3TC:
lamuvidine |
